



Jefferies Annual Healthcare Conference

June 2018

Dr. Reddy's Laboratories Limited

Hyderabad, India

BSE: 500124 | NSE: DRREDDY | NYSE: RDY

Dr.Reddy's 

Safe Harbor Statement

This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects” and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in India and other key global markets in which we operate;
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Allocations of funds by the Governments in our key global markets;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
- Changes in political conditions in India and in our key global markets.

Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements.

For more detailed information on the risks and uncertainties associated with the Company’s business activities, please see the Company’s Form 20-F for the fiscal year ended March 31, 2017, and Form 6-K for the quarters ended June 30, 2017, September 30, 2017 and December 31, 2017 and other filings with the US SEC. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events

Contents


Our Purpose

Company Overview

Recent Business Highlights

Growth Roadmap

Optimistic Future



Our Purpose

We accelerate access
to affordable and
innovative medicines

Because

**Good Health
Can't Wait.**

Our Purpose Guides Our Customer Value Proposition Leading to Specific Strategic Choices

PURPOSE

OUR PROMISES

We accelerate access
to affordable medicines
because

**Good Health
Can't Wait.**



Bringing expensive medicine within reach

Addressing unmet patient needs

Helping patients manage disease better

Enabling and helping our partners ensure our medicines are available where needed

Working with partners to help them succeed



COMPANY OVERVIEW



Multidimensional business model to sustain long-term growth

	UNBRANDED (US + EU)	BRANDED (EM + INDIA)	PROPRIETARY PRODUCTS
Current	<ul style="list-style-type: none">• Monetize the complex/ limited competition assets across channels and classes of trade	<ul style="list-style-type: none">• Continued growth for mega brands through patient centric initiatives• Selective business integration on NCE assets	<ul style="list-style-type: none">• Maximize the base business revenues through volume growth initiatives and managed care strategy
Future	<ul style="list-style-type: none">• Accelerate Biosimilars filings in US and EU• Outreach model for novel dosage forms in Non-traditional channels	<ul style="list-style-type: none">• Accelerate the journey to monetize Biosimilars assets across existing and new markets	<ul style="list-style-type: none">• Focus on development and filing of late-stage, high-value differentiated assets

PSAI

Leverage Industry leading chemistry skills to synthesize complex APIs enabling robust portfolio across the businesses



Recent Business Highlights



FY18 Financial Performance

FY18 Revenues

USD 2,181 M

(YoY growth: 1%)

FY18 EBIDTA

USD 370 M

(% of Sales: 17%)

FY18 FCF

USD 93 M

FY18 PBT

USD 220 M

(YoY decline: 2%)

FY 18 R & D Expenses

USD 281M

(% of Sales: 12.9%)

Net Debt / Equity

0.24

Highlights of FY18

Filings

Good filings performance

19 ANDAs & 1 NDA filed in the USA

Observations

No critical observations in multiple regulatory inspections in **CTOs**. **FTO2** and **FTO3** cleared regulatory hurdles

Product launches

Exciting new product launches in NAG like **Sevelamer, Lipo Dox, Palonosetron Inj, OTC Levocetirizine**

Markets

India Business performance post-GST picked up pace for the rest of FY18

New markets in **EM** showed positive early performance trends

PSAI

service levels to customers started showing improvement towards end of the year

Cost Control

in the organization helped partially offset revenue challenges

Delivering affordable generic alternatives in Unbranded Markets

15 NEW PRODUCTS LAUNCHED IN
NORTH AMERICA IN FISCAL 2018

First-To-Market launches of Palonosetron for Injection and OTC Levocetirizine Tablets

- Affordable alternative for complex, limited-competition products
- Multiple limited-competition launches this fiscal year (Incl. Sevelamer, Doxorubicin Hydrochloride Liposome Injection, Bivalirudin for Injection, and Ezetimibe & Simvastatin Tablets)

Other Product Launches in the U.S.

- Melphalan Hydrochloride 50mg Powder for Injection
- Clofarabine Injection for Intravenous Use
- Metaxalone Tablets
- Cefixime for Oral Suspension

Pipeline Updates

- Positive DC outcome on Suboxone litigation
- Launch preparations on track for on near-term **big-ticket** launches



Biosimilars and small molecule Oncology assets fueling global expansion

Successful launches of Oncology products in EM and EU

- Colombia, Brazil, Algeria, Spain, Italy


Reditux™ paving the way for the entry of upcoming Biosimilar assets in new markets

- Currently approved in 17 countries and available in 14

Launched five products in India through strategic collaboration with Amgen



Entry into more new markets in LatAm, Africa and Asia slated for H2 FY 18



Addressing unmet needs in Derma and Neurology

Commercial Updates

- First set of launches **Zembrace™** and **Sernivo™** ramping up well, continue to focus on accelerating the commercial business' path to profitability
- Promius Pharma recognized as an **emerging R&D driven commercial organization** in the neurology and dermatology communities

R&D Updates

- Filed the NDA for migraine candidate DFN-02
- Developing robust R&D Pipeline – **Three assets** in Phase III and **Three assets** in Phase II respectively

BD Updates

- Out-licensing of **DFD-06, a topical high potency steroid**, to Encore Dermatology
- Global License & Commercialization Agreement for Phase III Clinical Trial Candidate (**DFA 02**) for **Mitigation of Surgical Site Infections** with CHD Biosciences



Our Quality Journey

WE ARE COMMITTED TO
EXCELLENCE IN QUALITY
AND TO BEING THE BEST
IN THE INDUSTRY

U.S. FDA Audit Updates

Sites Previously on Warning Letter

CTO 5: Three observations in audit - Received EIR

CTO 6: Received EIR: compliance pending

FTO 7 Sterile Plant: Received EIR: compliance pending, anticipating re-audit in H2 2018

Other Sites

CTO SEZ: Concluded with zero observations

CTO 3: Concluded with five observations

CTO 1: Concluded with four observations

FTO 3 Bachupally: Received EIR

Mirfield: Concluded with three observations

Mexico: Concluded with zero observations

CPS Technology Development Center: Received EIR

FTO SEZ PU – 01 & 02: Received EIR





Growth Roadmap



North America Generics: Growth driven by limited competition products

2018

2021

Portfolio

- Oral solid dosages account for almost 80% of the current revenues
- Injectables accounting for 20% of the revenues

- More than 50% of revenues to come from Injectables, Topicals and other complex dosage forms
- Initiate monetization of Biosimilars assets

Channel

- Retail is the predominant class of trade for the business contributing more than 60% of current revenues
- Current OTC presence broadly in private Label segment

- Specialized channels like Oncology Clinics, Hospitals, OTC are expected to form 60% of the mix
- OTC Brands to become relevant part of business

Customer

- Exclusive focus on trade partners across retailers, Distributors and GPOs

- Increased relevance of other stakeholders like Patients, Physicians and Payors

Plant


- More than 70% revenues reliant on internal manufacturing sites

- Diversified manufacturing network with almost 50% of revenues coming from partner manufacturing sites

Healthy Pipeline of First-to-market, Tough-to-make Products

Bringing Expensive Medicine within Reach

NUMBER OF PENDING FILINGS* BY DOSAGE FORM



PIPELINE HIGHLIGHTS

107 pending ANDAs & 3 pending NDAs (505b2s)

- No incl. 63 para-IV and 30 first to file products

Portfolio of products based on:

- Complex Characterization / Analytical chemistry
- Novel regulatory pathway
- Large & complex clinical / Bio-studies
- High technology barrier in development & manufacturing

Fast-following on potential OTC switches

India & Emerging Markets : Growth driven by patient centric initiatives

2018

2021

India

- Focus on mega brands expansion
- Improvement in new launch productivity

- Portfolio augmentation and productivity improvement
- Step-up in Chronic and Super-specialty therapies
- Strategic business development and M&A efforts
- Differentiated assets in relevant therapies
- Focus on new growth avenues [a] Institution / Corporate hospitals; [b] OTC and Nutritionals

EM

- Focus on mega brands expansion / improvement in field force productivity
- Launch of Biosimilar products in existing markets

- Leveraging the Complex generics / Biosimilar portfolio, across markets
- Increase depth in lead geographies of Russia, Brazil & China
- Expanding presence in new markets
- Selective business integration for OTC / differentiated assets
Augment the capacities by establishing local manufacturing capabilities


Biologics: Maximizing value of current assets in near to mid-term while pursuing global development

BIOLOGICS REVENUE HAS GROWN AT APPROX. 30% CAGR OVER THE LAST 10 YEARS

EU/US approval enabling studies initiated for pegfilgrastim

Rituximab and bevacizumab approval enabling studies for EU/US expected to be initiated in next 4 - 6 quarters

2 new molecules entering clinical development in next 12 months



Above diagram depicts calendar years

Biologics: Creating substantial value in long term from new portfolio choices while driving R&D productivity

FY20 Product Portfolio

6 commercial products; > 50 filings across 14 major countries

5 new products in clinical development

FY20 Business Profile

Strong and relevant play in Emerging Markets

Developed Markets Royalties expected to Kick-in

FY25 Business Profile

Emerging Markets Revenue: \$300Mn – \$400Mn

Developed Markets Profits: > \$100Mn

EBITDA margin post R&D: > 35 %

Proprietary Products: Aspiring to build a \$400 million business by FY22 through a low-risk innovation model

- Established with the goal to address unmet needs of specific patient segments in Dermatology & Neurology
- Diverse portfolio of R&D assets with a track record of regulatory success
- Licensed three clinical stage assets to augment overall long term value of the portfolio
- Strong track record of commercial success – 33% CAGR top-line growth [FY11-FY17]

Specialty Dermatology Franchise

- 3 Products approved; 1 asset commercialized and 2 licensed
- Supported by 60 Sales Reps in 6 Regions

Specialty Neurology Franchise

- Introduced the Neurology franchise through the launch of Zembrace in 2016
- Supported by 45 Sales Reps in 6 Regions

FDA Approval for Five NDAs (organic pipeline assets) ➤ Two Launched April/May 2016

ZEMBRACE™ SymTouch™ (sumatriptan injection) 3 mg/ 0.5 mL
Sernivo™ (betamethasone dipropionate) Spray, 0.05%

Aurigene: Specialized Biotech division focused on addressing critical needs in Oncology and Auto-immune therapeutic areas

BUSINESS MODEL

- Focused on Oncology & inflammation disorders
- Complementing infrastructure for small molecule & peptide drug discovery
- Client value proposition characterized by collaboration & licensing
- Multi-year collaborations with 6 of top-10 pharmaceutical companies



OUTCOMES

- 70+ integrated discovery programs resulting in over 135 patents in the last 10 years
- Out-licensed multiple early-stage and late stage programs
- 11 INDs filed under collaboration programs; multiple assets in Phase I/II
- Pipeline of programs in Immuno-oncology, Epigenetics & Th17 pathway



OPTIMISTIC FUTURE



Key Strategic Priorities



Strengthening Manufacturing & Quality

Create culture encouraging **Transparency** and **Compliance**



Creating Leaner and Flexible cost structures

Focus on Manufacturing and R & D Network **Rationalization**, Improving Plant Operating **Efficiency**, R&D **Productivity** and Portfolio **Optimization**



Assuring Long-Term Growth across all our businesses

Focus on delivering **Top 30 products** accounting for 50% of incremental growth



**Good
Health
Can't
Wait.**

Contacts

Investor relations

Saunak Savla

saunaks@drreddys.Com

(Ph: +91-40-49002135)

Media relations

Calvin Printer

calvinprinter@drreddys.Com

(Ph: +91-40-49002121)

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues.

The company assumes no obligation to update any information contained herein.

Registered Office: Dr. Reddy's Laboratories Ltd. 8-2-337 | Road No. 3, Banjara Hills, Hyderabad - 500034, Telangana, India.

Tel: 91 40 4900 2900 | **Fax:** 91 40 4900 2999 | **Web:** www.drreddys.com